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Sudden Unexpected Death After
Balloon Valvuloplasty for Congenital Aortic Stenosis
David W. Brown, MD, Amy E. Dipilato, BA, Erin C. Chong, BA, Kimberlee Gauvreau, SCD,
Doff B. McElhinney, MD, Steven D. Colan, MD, James E. Lock, MD
Boston, Massachusetts
Objectives The aims of this study were to determine the incidence and risk factors of sudden unexpected death (SUD)
after balloon aortic valvuloplasty (BAVP) for congenital aortic stenosis (AS) and to assess the effect of exer-
cise restriction.
Background Exercise restriction is recommended for some patients with congenital AS because of a perceived increased risk
for SUD. Little is known about the incidence of SUD in those with treated AS or the efficacy of exercise restric-
tion in preventing SUD.
Methods A review was conducted of 528 patients who underwent BAVP for congenital AS at Children’s Hospital Boston
from 1984 to 2008. Exercise restriction status was ascertained for those 4 years of age, censored at aortic
valve replacement or transplantation.
Results Median subsequent follow-up was 12.0 years (range 0 to 24.8 years), for a total of 6,344 patient-years of follow-
up. There were 63 deaths, with SUD in 6 patients, 5 of which occurred at 18 months of age. For patients 4
years of age at most recent follow-up with no histories of pulmonary hypertension (n  422), median follow-up
after BAVP was 14.6 years, for 6,019 patient-years of follow-up. Exercise restriction was prescribed in 183 pa-
tients (43%; 2,541 patient-years) and no restriction in 220 (52%; 2,691 patient-years); there were insufficient
data in 19 patients. There were 17 deaths in this cohort of 422 patients, with 1 SUD (the patient, who was exer-
cise restricted, died during sleep), for an incidence of 0.18/1,000 patient-years (95% confidence interval: 0.01
of 1,000 to 1.01 of 1,000).
Conclusions SUD is extremely rare after BAVP for congenital AS. No beneficial effect of the recommendation for exercise re-
striction was observed in this longitudinal cohort with 6,000 patient-years of follow-up. (J Am Coll Cardiol
2010;56:1939–46) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.048r
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tince first reported 25 years ago (1), balloon aortic valvu-
oplasty (BAVP) has gradually become the preferred treat-
ent for newborns, children, and young adults with con-
enital aortic stenosis (AS) at most centers (2–8). Although
his treatment is usually effective for acutely relieving left
entricular outflow obstruction, a number of studies of
hort-term and midterm outcomes of BAVP for congenital
S have demonstrated subsequent progressive aortic valve
isease in some patients, both stenosis and regurgitation
3,5–7,9). Long-term outcomes are less well characterized
ut suggest a steady long-term hazard for aortic valve
eplacement (AVR) (8–10).
rom the Department of Cardiology, Children’s Hospital and Department of
ediatrics, Harvard Medical School, Boston, Massachusetts. This study was sup-
orted by the Higgins Family Fund and the Dunlevie Family Fund. All authors have
eported that they have no relationships to disclose.(
Manuscript received January 14, 2010; revised manuscript received June 18, 2010,
ccepted June 21, 2010.Sudden unexpected death (SUD) has been documented
arely in both symptomatic and asymptomatic patients with
evere congenital AS (11,12). Large case series and registries
f athletes who died suddenly have included small numbers
f patients with congenital AS (13,14). Consensus expert
anel recommendations have thus been developed that
estrict patients with congenital AS from strenuous exercise
nd competitive sports to varying degrees, such as the 36th
See page 1947
ethesda Conference (15), with similar recommendations
ndorsed by national organizations, including the American
eart Association and American College of Cardiology
16). In brief, these recommendations restrict asymptomatic
atients with moderate AS (defined as a maximal instanta-
eous Doppler gradient of 40 to 70 mm Hg) from some
ypes of competitive sports, and those with severe AS
maximal instantaneous Doppler gradient 70 mm Hg)
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Patients with treated AS are re-
stricted from competitive sports
on the basis of subsequent resid-
ual gradients after intervention
by the same criteria.
Few long-term studies, how-
ever, have been performed in pa-
tients with congenital AS, and
the data on which these recom-
mendations are based are largely
from case reports and series. In
the Second Natural History
tudy of Congenital Heart Defects, SUD occurred in 25 of
62 patients with congenital AS followed for an average of
ore than 15 years; however, the majority of these patients
ad undergone surgical valvotomy (11). The true incidence
nd risk factors for SUD in patients treated with modern
ranscatheter techniques are unknown. There is little evi-
ence that exercise increases the risk for SUD in patients
ith treated congenital AS, and such recommendations are
t odds with the known beneficial effects of regular exercise
n maintaining cardiovascular health (17). Highly divergent
iews among physicians at our institution about the appro-
riateness of exercise and competitive sports restriction in
atients followed noninvasively with known congenital AS
ave thus resulted in significant practice variation. We
ought to determine the incidence and risk factors for SUD
n a large cohort of patients who underwent BAVP for
ongenital AS over a 24-year period and to determine if a
eneficial effect of exercise restriction in preventing SUD
ould be demonstrated.
ethods
atients. Patients with congenital valvular AS who un-
erwent transcatheter BAVP at Children’s Hospital Bos-
on from December 1984 through January 2009 were
scertained from the computer database of the Depart-
ent of Cardiology. Patients who were converted to a
unctionally univentricular circulation within 30 days of
atheterization were excluded. Patients who underwent
rior surgical or transcatheter aortic valve intervention
efore referral to our center were included, as were those
ith associated congenital cardiovascular anomalies;
atent ductus arteriosus in newborns, patent foramen
vale, and atrial septal defects not treated surgically were
ot considered “associated cardiovascular anomalies.” In-
ications for catheterization and valve dilation were not
tandardized and may have varied according to patient
ge, clinical status, era, referring physician, and interven-
ional cardiologist. General guidelines for intervention
onsidered symptomatic status, AS gradient, ventricular
unction, and the presence and severity of associated
nomalies. From 1985, BAVP was the preferred therapy
Abbreviations
and Acronyms
AS  aortic stenosis
AVR  aortic valve
replacement
BAVP  balloon aortic
valvuloplasty
CI  confidence interval
HR  hazard ratio
SUD  sudden unexpected
deathor congenital AS at our center, and surgical aortic galvotomy would have been performed almost exclusively
n patients with coexisting anomalies requiring open-
eart surgery, or after unsuccessful balloon dilation. The
echnical details of BAVP have been described pre-
iously (2,3,5).
Cross-sectional follow-up was obtained by June 2009.
atients not followed longitudinally at our center were
ontacted by mail and subsequent telephone call detailing
he study. Exercise restriction status was considered relevant
or patients 4 years of age at most recent follow-up and
as ascertained by review of clinical records and/or verified
y direct inquiry. Because of complex clinical variation in
he nature and degree of restriction from exercise, we
implified our analysis by considering patients “restricted” if
heir cardiologist had placed any restrictions on exercise or
ompetitive sports participation. Patients with histories of
ulmonary hypertension, which was defined as mean pulmo-
ary artery pressure30mmHg at an age30 days, were also
xcluded from the exercise restriction portion of the analysis,
ecause this represents a known risk factor for sudden death
nd separate indication for exercise restriction. Most recent
ollow-up echocardiographic data were collected (before AVR
f applicable), and maximal instantaneous AS gradient by
oppler was categorized according to the cutoffs recom-
ended in the Bethesda guidelines: mild, 40 mm Hg;
oderate, 40 to 70 mm Hg; and severe, 70 mm Hg (15).
Patients were considered lost to follow-up if there was no
vailable contact information and no known clinical
ollow-up for 4 years. For these patients (n  48), vital
tatus and cause of death (if deceased) were ascertained by
uery of both the Social Security Death Index (maintained
y the Social Security Administration) and the National
eath Index, a large database maintained by the U.S.
epartment of Health and Human Services, Centers for
isease Control and Prevention, and the National Center
or Health Statistics.
ata analysis. The primary outcome was SUD in patients
ith biventricular circulation after BAVP. Secondary out-
omes included cardiovascular death and all-cause mortality.
aplan-Meier analysis with log-rank testing and Cox pro-
ortional hazards regression were performed to assess the
elationship between predictor variables and time to event,
ith the start time set at the initial BAVP procedure. Variables
ignificant at the 0.10 level by the log-rank test were considered
or inclusion in the multivariate Cox model; a forward selection
rocedure was used. Variables significant at the 0.05 level on
he basis of a likelihood ratio test were retained in the final
odel. Patients were censored at time of first use of AVR or
eart transplantation. Comparisons between patients with and
ithout exercise restriction were performed using the Wil-
oxon rank sum test for continuous variables and the Fisher
xact test for categorical variables.
This retrospective study was performed according to a
rotocol approved by the Committee for Clinical Investi-
ation at Children’s Hospital Boston.
RP
p
H
f
f
p
r
a
t
t
a

(
c
A
g
d
s
h
e
a
t
e
b
F
w
p
w
f
t
n
t
D
p
(
i
v
DB
*
t
a
t
v
3
PA
*
g
MP
*
a
r
1941JACC Vol. 56, No. 23, 2010 Brown et al.
November 30, 2010:1939–46 Sudden Death in Congenital ASesults
atients. Between December 1984 and January 2008, 563
atients with congenital AS underwent BAVP at Children’s
ospital Boston. Thirty-five of these patients were excluded
rom the present study because they were converted to
unctionally univentricular circulation during the same hos-
italization, either as part of a planned strategy of left-heart
ehabilitation or because of circulatory insufficiency after
ortic valve dilation. The remaining 528 patients constituted
he study cohort. Demographic and diagnostic details of
hese 528 patients are summarized in Table 1. The median
ge at BAVP was 1.9 years, and most patients (75%) were
10 years of age. The majority had isolated valvular AS
n  334 [63%]), and most (n  384 [73%]) had no other
ardiac interventions before BAVP.
Most patients (n 447 [85%]) had pre-intervention peak
S gradients 50 mm Hg at catheterization. The peak AS
radient decreased significantly after balloon dilation (me-
ian acute decrease, 35 mm Hg; p  0.001 by Wilcoxon
igned rank test). Pre- and post-intervention aortic valve
emodynamic variables are summarized in Table 2. Mod-
rate or worse AR was present in 14% of the cohort by
ngiography acutely after BAVP. Approximately 100 of
hese 528 patients were included in a previous report that
emographic and Diagnostic Data at Time of FirstAVP for Congenital AS, 1984 to 2009 (n  528)Table 1 Demographic and Di gnostic Data a Time of FirstBAVP for Congenital AS, 1984 to 2009 (n  528)
Variable Value
Age
Median (range) 1.9 yrs (1 day to 40.4 yrs)
Group
1 month 128 (24%)
1–12 months 121 (23%)
1–10 yrs 147 (28%)
11 yrs 132 (25%)
Associated congenital cardiovascular anomalies*
None 334 (63%)
Coarctation/IAA 95 (18%)
Mitral stenosis† 55 (10%)
Multiple left-heart obstructions‡ 38 (8%)
Ventricular septal defect 43 (8%)
Other§ 3 (1%)
Pulmonary hypertension 37 (7%)
Prior interventions
None 384 (73%)
Prior intervention for AS 75 (14%)
Surgical valvotomy 57 (11%)
Balloon dilation 21 (4%)
Coarctation/IAA repair 71 (13%)
Ventricular septal defect closure 22 (4%)
Subaortic stenosis procedure 20 (4%)
Some had more than 1 associated congenital cardiovascular anomaly. †Defined as mean
ransmitral Doppler gradient 4 mm Hg. ‡AS plus at least 2 of the following: coarctation of the
orta, mitral stenosis, and subaortic stenosis. §One case each of transposition of the great arteries,
etralogy of Fallot, and sinus venous atrial septal defect with partially anomalous pulmonary
enous return. Defined as mean pulmonary artery pressure at catheterization 30 mm Hg, past
0 days of age.
AS  aortic stenosis; BAVP  balloon aortic valvuloplasty; IAA  interrupted aortic arch.
uvaluated factors associated with anatomic suitability for
iventricular repair in newborns with AS (18).
ollow-up. The median duration of vital status follow-up
as 12.0 years (range 0.1 to 24.8 years), for a total of 6,344
atient-years of follow-up (Table 3). Among 488 patients
ho underwent balloon dilation before 2006, clinical
ollow-up data were available for at least 2 years or until the
ime of death in all but 6. Among more recent patients,
one met our definition of loss to follow-up, although in 6,
he most recent follow-up was 2 months after dilation.
uring follow-up, repeat BAVP was performed in 117
atients (22%), for a total of 149 repeat procedures. AVR
including the Ross procedure) was subsequently performed
n 116 (22%). Further analyses of patient and procedural
ariables associated with long-term valve function and
re-BAVP and Acute Post-BAVPortic alve Function (n  528)Table 2 Pre-BAVP and Acute Post-BAVPAortic Valve Function (n  528)
Variable Value
Pre-intervention peak AS gradient (mm Hg)*
Median (range) 65 (0–160)
49 78 (15%)
50–79 310 (59%)
80 137 (26%)
Acute post-dilation peak AS gradient (mm Hg)†
Median (range) 28 (0–106)
29 269 (51.5%)
30–39 144 (27.5%)
40 109 (21%)
Acute post-dilation AR severity‡
None-trace 275 (52%)
Mild 178 (34%)
Moderate or severe 74 (14%)
Data missing in 3 patients. †Data missing in 6 patients. ‡Data missing in 1 patient. AR was
raded by catheter angiography.
AR  aortic regurgitation; other abbreviations as in Table 1.
ost Recent Follow-Up Afterost-BAVP for Congenital AS (n  528)Table 3 Most R cent Follow-Up AfterPost-BAVP for Congenital AS (n  528)
Variable Value
Age (yrs), median (range) 17.9 (0–64)
Duration follow-up (yrs), median (range) 12.0 (0–24.8)
Cumulative follow-up (patient-yrs) 6,344
Repeat BAVP* 117 (22%)
AVR 116 (22%)
Age 4 yrs at most recent follow-up 422
Exercise restrictions (any)† 183 (43%)
Cumulative restricted follow-up (patient-yrs) 2,541
No exercise restrictions‡ 220 (52%)
Cumulative unrestricted follow-up (patient-yrs) 2,691
Restrictive cardiomyopathy 5 (1%)
Heart transplantation 5 (1%)
Death 63 (12%)
30 patients had1 repeat dilation. †Exercise restriction considered relevant in those4 years of
ge at most recent follow-up (n  454); 32 patients had pulmonary hypertension. Includes any
estriction from weightlifting, competitive sports, or exercise. Exercise restriction data were
navailable in 19 patients. ‡Censored at the time of AVR or transplantation.
AVR  aortic valve replacement; other abbreviations as in Table 1.
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Sudden Death in Congenital AS November 30, 2010:1939–46eintervention after BAVP are the subject of another study
nd were not further investigated for the purposes of this
eport.
xercise restriction. Among 422 patients 4 years of age
t most recent follow-up and without pulmonary hyperten-
ion, median follow-up after BAVP was 14.6 years, for total
,019 patient-years of follow-up (Table 3). Exercise restric-
ion was able to be defined from medical records and/or
atient inquiry in 403 patients (not available in 19), with
83 (43%) exercise restricted and 220 (52%) not restricted.
o cases of “crossover” from exercise restricted to unre-
tricted, or vice versa, were noted. Cumulative follow-up in
he 2 groups was similar: 2,541 patient-years for exercise-
estricted patients versus 2,691 patient-years for those
nrestricted.
Exercise-restricted and unrestricted patients did not differ
ith regard to baseline demographics, anatomic features, or
eri-BAVP hemodynamic status (Table 4). The median
uration of follow-up was longer in the exercise-restricted
roup (14.4 years vs. 12.1 years), although as noted previ-
usly, the cumulative patient-years of follow-up were sim-
lar. The proportion of patients who had undergone repeat
AVP before cross-sectional follow-up was similar in both
roups (24%), although more had undergone AVR in the
estricted group (33%) than the unrestricted group (20%).
easures of aortic valve function by echocardiography at
ost recent follow-up showed a modestly but not signifi-
Comparison of Exercise-Restricted VersusUnrestricted Patients After BAVP for CongenitaTable 4 Compari on of Exercise-RestrictedUnrestricted Patients After BAVP fo
Factor
Age at BAVP (yrs)
Associated CHD
Pre-intervention peak AS gradient (mm Hg) (n  181,219)
Acute post-dilation peak AS gradient (mm Hg) (n  181,21
Acute post-dilation AR severity
None-trace
Mild
Moderate or severe
Cumulative follow-up (patient-yrs)†
Follow-up (yrs)
Repeat BAVP
AVR
Most recent echocardiographic AS gradient (MIG, mm Hg)‡
Mild (40)
Moderate (40–70)
Severe (70)
Most recent echocardiographic AR  moderate‡
Transplantation
Death (any)
SUD
Data are expressed as median (range) or as number (percent). The p
years of age at most recent follow-up, with no histories of pulmona
†Censored at the time of AVR or transplantation. ‡Data were availab
CHD congenital heart disease; MIGmaximal instantaneous gra
Tables 1 to 3.antly higher AS gradient in those restricted from exercise wmedian maximal instantaneous gradient, 44 mm Hg vs. 41
m Hg; p  0.60). In both restricted and unrestricted
atients, the distribution of AS gradients was skewed, but
ost patients had moderate or severe AS in both groups
Fig. 1). The proportion of patients with severe AS (max-
mal instantaneous Doppler gradient 70 mm Hg) was not
ignificantly different between exercise-restricted and unre-
tricted patients (11% vs. 9%, p  0.73). The proportion of
atients with moderate or worse aortic regurgitation was
imilar in both groups.
eaths. Sixty-three of 528 patients died during follow-up,
ith death from cardiovascular causes in 50 patients.
wenty of these occurred within 1 month of BAVP.
urvival over time was 95  1% at 5 years, 93  1% at 10
ears, and 88  2% at 20 years by Kaplan-Meier analysis,
ith a steep early hazard for death, followed by a steady
azard (Fig. 2). Among patients 4 years of age at most
ecent follow-up (n  423), there were 20 total deaths, 17
f which occurred in patients in whom exercise restriction
tatus could be ascertained (Table 4, Figs. 3 and 4).
The causes of death for the whole cohort included
ongestive heart failure (primarily infants with circulatory
ailure after BAVP; n 27), operative complications during
r after aortic or mitral valve surgery (n  9), pneumonia or
epsis (n  4), accidental death (n  3), acute catheteriza-
ion complications (n  2), and drug overdose (n  2); a
omplete list is provided in Table 5. Five patients under-
n  403)*s
ngenital AS (n  403)*
Exercise Restricted
(n  183)
Unrestricted
(n  220) p Value
4 (0–29) 3 (0–35) 0.09
58 (32%) 73 (33%) 0.83
65 (10–160) 65 (6–130) 0.59
30 (0–90) 28 (0–106) 0.36
0.47
87 (48%) 118 (54%)
65 (35%) 68 (31%)
31 (17%) 34 (15%)
2,541 2,691 —
14.4 (0.2–24.8) 12.1 (0.0–24.4) 0.01
43 (24%) 52 (24%) —
60 (33%) 45 (20%) —
44 (0–120) 41 (0–115) 0.60
66 (41%) 86 (45%) 0.73
78 (48%) 89 (46%)
17 (11%) 17 (9%)
49 (27%) 56 (26%) 0.82
1 (1%) 1 (1%) —
11 (6%) 6 (3%) —
1 (1%) 0 (0%) —
re not reported for time-dependent variables. *Includes patients 4
rtension. Exercise restriction data were unavailable in 19 patients.
but 50 patients: 22 restricted and 28 unrestricted.
Doppler; SUD sudden unexpected death; other abbreviations as inl AS (Versu
r Co
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November 30, 2010:1939–46 Sudden Death in Congenital ASequently died. Among patients with diagnoses of pulmo-
ary hypertension, 46% died during follow-up, compared
ith 6.7% of those without this diagnosis.
In multivariate analysis, age 30 days at BAVP (hazard
atio [HR]: 5.7; 95% confidence interval [CI]: 3.2 to 10.1;
 0.001), presence of multiple left-sided obstructive
esions (HR: 11.9; 95% CI: 5.9 to 24.4; p  0.001), and
AVP during the first decade of experience (HR: 5.9; 95%
I: 2.3 to 15.1; p  0.001) were the only pre-procedural or
Figure 1 AS Gradient at Most Recent Follow-Up
Histograms demonstrate the maximal instantaneous gradient by Doppler echo-
cardiography at most recent follow-up in unrestricted and exercise-restricted
patients. Follow-up data were not available in 28 of 220 unrestricted and 22 of
183 exercise-restricted patients. AS  aortic stenosis.
Figure 2 Survival After BAVP for Congenital AS
Kaplan-Meier survival analysis of entire cohort of patients who underwent bal-
loon aortic valvuloplasty (BAVP) for congenital aortic stenosis (AS) from 1984
to 2009 (n  528). Solid line represents estimated probability of survival, with
dashed lines demonstrating 95% confidence bands.cute post-procedural predictors of subsequent cardiovascu-
ar death.
udden deaths. Of the 63 deaths in the entire cohort, 6
ere considered SUD (Table 6). Five of these patients died
t 18 months of age and 3 at 2 months of age. Only 1
UD occurred in the group 4 years of age at most recent
ollow-up, a 28-year-old asymptomatic patient who was
estricted from competitive sports, who died suddenly dur-
ng sleep. Thus, the minimal incidence of SUD in the
ohort 4 years of age was 18 of 100,000 patient-years
95% CI: 1 of 100,000 to 101 of 100,000). Although patient
ollow-up for the purpose of SUD was censored at time of
Figure 3 Survival After BAVP for Congenital AS for Those
More Than 4 Years of Age at Most Recent Follow-Up
Kaplan-Meier survival analysis of patients 4 years of age, with no histories of
pulmonary hypertension, who underwent balloon aortic valvuloplasty (BAVP) for
congenital aortic stenosis (AS) (n  422). Solid line represents estimated
probability of survival, with dashed lines demonstrating 95% confidence bands.
Figure 4 Survival by Exercise Restriction Status
After BAVP for Congenital AS
Kaplan-Meier survival analysis of patients who had undergone balloon aortic
valvuloplasty (BAVP) for congenital aortic stenosis (AS) and were 4 years of
age at most recent follow-up, with no histories of pulmonary hypertension, by
exercise restriction status (any restriction from exercise or competitive sports
was considered restricted). Solid line indicates patients restricted from exer-
cise, and dashed line represents those unrestricted. Log-rank test p  0.30.
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Sudden Death in Congenital AS November 30, 2010:1939–46VR or transplantation by study design, SUD did not occur
n any patients censored for this reason.
iscussion
n this long-term observational cohort of 528 patients who
nderwent BAVP for congenital AS, we found an extremely
ow rate of SUD; there were only 6 cases in more than 6,300
atient-years of follow-up. Although the small number of
atients with SUD precluded formal statistical analysis for
ssociated variables, SUD was more common in the young,
ith 5 of 6 cases occurring in infants 18 months of age
nd 3 of the 6 cases in those 45 days of age. Patients with
eonatal AS requiring BAVP early in life may thus be at
igher risk than older children for SUD, a finding that has
ot been reported to date and may have implications for
linical follow-up.
Among patients 4 years of age at most recent follow-
p, in whom exercise restriction could reasonably be postu-
ated to have a beneficial or protective effect, we found only
single occurrence of SUD in more than 6,000 patient-
eaths After BAVP for Congenital AS (n  528)Table 5 Deaths After BAVP for Congenital AS (n  528)
Variable n (%)
Deaths 63 (12%)
Accident 3 (5%)
Acute catheterization procedural* 2 (3%)
Congestive heart failure† 27 (43%)
Drug overdose 2 (3%)
Endocarditis 1 (1.6%)
Heart transplantation complications 4 (6%)
Leukemia 1 (1.6%)
Pneumonia and/or sepsis 4 (6%)
Post-operative cardiac surgery complications 9 (14%)
Respiratory failure (Duchenne muscular dystrophy) 1 (1.6%)
Ruptured aortic aneurysm (Turner syndrome) 1 (1.6%)
Stroke (mechanical AVR, warfarin noncompliance) 1 (1.6%)
SUD 6 (10%)
Tracheal reconstruction surgery complications 1 (1.6%)
One death due to occlusive aortic flap raised over left coronary ostium, the other to lethal
entricular arrhythmia. †Primarily infants with circulatory insufficiency after BAVP.
Abbreviations as in Tables 1, 3, and 4.
UD After BAVP for Congenital ASTable 6 SUD After BAVP for Congenital AS
Patient #
Age at
BAVP*
Age at
Death Associated CHD
1 2 days 14 days Isolated valvular AS
2 1 day 30 days Isolated valvular AS
3 2 days 45 days Isolated valvular AS
4 24 days 18 months D-loop TGA, underwent arterial
switch operation
5 1 day 11 months Multiple left-sided obstructions,
pulmonary hypertension
6 6 yrs 28 yrs Aortic coarctation, underwent
coarctation repairAge at first BAVP procedure. Patients 5 and 6 had more than 1 BAVP. †At most recent follow-up, Dopp
TGA  transposition of the great arteries; other abbreviations as in Tables 1, 2, and 4.ears of follow-up. Cumulative patient-years of follow-up
ere roughly similar in the group of patients restricted in
ny fashion from exercise and those unrestricted (2,541
atient-years vs. 2,691 patient-years), and we could find no
ifferences between these groups in baseline characteristics
such as age at initial BAVP, frequency of associated
ardiovascular anomalies, or pre-intervention AS gradient),
r acute procedural results (post-intervention AS gradient,
egree of AR). There were no obvious differences in
ubsequent outcomes, with 24% of patients in both groups
equiring repeat BAVP and similar number requiring heart
ransplantation (1 patient in both groups). Although the
edian AS gradient by most recent echocardiogram was
lightly higher in the exercise-restricted group (44 mm Hg
s. 41 mm Hg), and although the exercise-restricted group
as more skewed toward higher gradients, as shown in
igure 1, the majority of patients in both groups would be
lassified as having moderate or greater AS by the Bethesda
uidelines. A similar proportion in both groups had mod-
rate or worse aortic regurgitation by most recent echocar-
iogram. There were more AVR procedures in the re-
tricted group (33% vs. 20%), although given the known
teady risk for AVR in this population (8–10), this may be
t least partially explained by a longer median follow-up
ime in the exercise-restricted group (14.4 years vs. 12.1
ears). Thus, within the constraints of this retrospective
tudy, although some differences between the 2 groups, such
s AS gradient at most recent follow-up, exist, the decision
o restrict patients from exercise or sports participation did
ot appear to be determined by clinical factors alone but in
arge part by the practice pattern of the treating cardiologist,
resumably informed by his or her interpretation of national
uidelines such as the Bethesda Conference (15). The issue
f how patients followed such recommendations could not
e ascertained by this study design. Despite a large number
f patient-years of follow-up, we did not observe a beneficial
ffect of the recommendation for exercise restriction in
reventing SUD.
This study included only patients with congenital AS
ho had undergone BAVP. Patients with congenital AS
al Residual
AR‡ Circumstances of Sudden Death
Mild At home, no preceding symptoms. Autopsy performed,
no clear etiology found.
Trivial At home, no preceding symptoms. Autopsy not performed.
Mild At home, no preceding symptoms. Autopsy not performed.
Mild At home, no preceding symptoms. Autopsy not performed.
Moderate At home, fever and respiratory symptoms. Autopsy
performed, sepsis listed as primary cause of death.
Moderate At home while sleeping, no preceding symptoms. Autopsy
not performed.Residu
AS†
35
40
40
35
40
65ler maximal instantaneous gradient. ‡At most recent follow-up.
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November 30, 2010:1939–46 Sudden Death in Congenital ASho underwent surgical valvotomy as primary treatment of
heir disease, or with AS not severe enough to require
ntervention, were not included. At our center, surgical
alvotomy was primarily used in an earlier treatment era,
efore the advent of BAVP in the mid-1980s, and since that
ime has been used nearly exclusively for patients undergo-
ng surgical repair of other significant congenital heart
esions, which may modify the subsequent natural history,
r for BAVP treatment failures. Patients with congenital
S who did not undergo BAVP during the study period
ere primarily those with milder forms of the disease, and
hey were not included in this report for a number of
easons, including the known inaccuracy of noninvasive
oppler determinations of the severity of AS in children
19) as well as the presumed lower risk for SUD in those
ith mild disease as informed by previous natural history
tudies (11). As congenital valvular AS often worsens over
ime, the number of patients followed at our center with
ignificant AS in which BAVP was not undertaken over the
4-year time period of this study was relatively small. Our
tudy focused on a group with severe enough AS by invasive
easurement to require BAVP, which represents a popula-
ion with the most severe disease and presumably the
ighest risk for SUD.
Case series (12) and large cohort studies (11) have
uggested that patients with symptoms and the highest AS
radients are at higher risk for SUD. Although such
etrospective data have been used to inform national guide-
ines regarding exercise restriction and restriction from
ompetitive athletics (15,16), patients with severe, symp-
omatic, untreated AS are rarely encountered clinically in
he current era. This study of patients with congenital AS
anaged with more contemporary BAVP techniques would
ndicate that the absolute risk for SUD is extremely low,
ith a reasonably long cohort follow-up in both exercise
estricted and unrestricted patients. In contrast, there has
een mounting evidence that regular exercise offers a num-
er of health benefits, including improved survival and lower
isk for cardiovascular events (17) in normal patients and
mproved functional capacity and quality of life even in
atients with severe congenital heart disease (20–22).
hodes et al. (23) found a significant positive impact of
egular exercise on behavior, emotional state, and well-being
n patients with severe congenital heart disease. Although
he intent of competitive sports restriction is not to preclude
egular exercise for the maintenance of cardiovascular fit-
ess, patients may interpret such restriction as an indication
hat vigorous exercise may be detrimental to their health,
hich might have unintended negative consequences that
urpass any positive benefit. The full impact of restriction
rom competitive athletics on patients, including long-term
ardiovascular risk factors (such as sedentary life-style and
ody mass index), exercise capacity, and psychological
ell-being, has not been well studied to date but deserves
urther evaluation, particularly in light of the lack of a clear
eneficial effect on SUD. IOverall, the risk for cardiovascular death after BAVP was
ot associated with acute post-procedural hemodynamic
tatus. However, there were some significant predictors of
ubsequent cardiovascular death, most notably the presence
f multiple left-heart obstructions (HR: 11.9), a subset of
atients with congenital AS known to have significant
ssociated mortality (24–26). Many of these patients also
ad pulmonary hypertension, which was also associated
ith mortality in this study; 46% of patients diagnosed with
ulmonary hypertension at some point during follow-up
ied, compared with 6% in patients without this diagnosis.
atients undergoing BAVP during the first decade of
xperience had a higher risk for cardiovascular death than
hose treated in subsequent years. Patients undergoing
AVP as neonates also had a higher risk for cardiovascular
eath (HR: 5.7), often early after BAVP, which may be a
arker of more severe or progressive disease.
tudy limitations. One of the primary limitations of this
tudy is that the rarity of SUD in patients of exercising age
anaged with BAVP precluded insight into 1 of our central
linical questions: does exercise restriction prevent SUD in
atients with congenital AS? Other limitations to this study
re the retrospective study design and extended enrollment
eriod, logistic considerations that may limit the applicabil-
ty of our findings. Similarly, although general clinical
uidelines for intervention were followed, criteria for refer-
al for catheterization or BAVP were not standardized, and
ractice likely varied over time and among practitioners.
emodynamic variables likely changed over time in some
atients, but we did not attempt to account for the potential
ime variance in AS or aortic regurgitation. As a retrospec-
ive evaluation, the clinical decision making that informed
estricting or not restricting a given patient from competi-
ive sports or exercise was often not available, only the
rescription itself; we also did not verify the actual activity
evels of the patients. Other clinical information that might
actor into the decision to restrict from exercise, such as
lectrocardiographic changes, were not available in many
atients and thus were not included in the analysis. Fur-
hermore, the complex variation in types and levels of
xercise restriction, including changes in restriction status,
recluded a more complex analysis of the data. Also, many
f the patients in this cohort were primarily followed
lsewhere, and inquiry of the National Death Index and
ocial Security Death Index was required to ascertain vital
tatus in some patients; although these are highly sensitive
ools for ascertaining deaths and causes of death in most
tudies (27), it is possible that a small number of deaths were
ither missed or misclassified. However, given the rarity of
UD in this study, most of the methodological limitations
oted likely had little impact on our primary conclusions.
onclusions
UD is extremely rare after BAVP for congenital AS.
nfants may be at somewhat higher risk for SUD after
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Sudden Death in Congenital AS November 30, 2010:1939–46AVP. No beneficial effect of the recommendation for
xercise restriction was observed in this longitudinal cohort
ith 6,000 patient-years of follow-up. Current guidelines
hat restrict some patients with congenital AS from sports
articipation may overestimate the beneficial impact this
ractice has in preventing SUD.
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